Effect of erythropoietin on COVID-19

Phase 2

Recruiting

• Conditions: aboratory confirmed COVID-19.; COVID-19, virus identified; U07.1

• Registration Number: IRCT20200509047364N1
• Lead Sponsor: Bandare-abbas University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 June 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

All definitively positive COVID-19 patients with Hb=9.
Having at least one of the severe symptoms of COVID-19, including tachypnea (breathing rate> 30 beats per minute), hypoxemia (O2 =93 saturation, the partial pressure ratio of arterial oxygen <300), Lung infiltration (> 50% of lung field within 24 to 48 hours), progressive lymphopenia, LDH>245 U/I, CRP>100

Exclusion Criteria

Patients with a history of coagulopathy
Patients with a history of thrombosis
Patients with a history of deep vein thrombosis
Patients with a history of chronic lung disease
Patients with a history of diabetes mellitus
Patients with weakened immune systems
Patients with a history of end stage renal disease
Patients with liver disease
Patients with a history of taking oral contraceptive pills (OCPs)
Patients with systolic blood pressure greater than 160 mmHg
Patients with diastolic blood pressure greater than 90 mmHg
Patients over 65 years of age
Patients with erythropoietin above 500
Patients with a history of myocardial infarction or unstable angina
Patients with a history of malignancy

Study & Design

• Study Type: interventional
• Study Design: Not specified